Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash & Equivalents: 2009-2025

Historic Cash & Equivalents for Corcept Therapeutics (CORT) over the last 13 years, with Sep 2025 value amounting to $125.1 million.

  • Corcept Therapeutics' Cash & Equivalents fell 8.85% to $125.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.1 million, marking a year-over-year decrease of 8.85%. This contributed to the annual value of $127.7 million for FY2024, which is 5.82% down from last year.
  • Per Corcept Therapeutics' latest filing, its Cash & Equivalents stood at $125.1 million for Q3 2025, which was up 21.79% from $102.7 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Cash & Equivalents peaked at $299.9 million during Q1 2023, and registered a low of $35.3 million during Q2 2022.
  • Moreover, its 3-year median value for Cash & Equivalents was $128.6 million (2024), whereas its average is $143.7 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first tumbled by 62.96% in 2022, then surged by 387.68% in 2023.
  • Corcept Therapeutics' Cash & Equivalents (Quarterly) stood at $77.6 million in 2021, then dropped by 14.54% to $66.3 million in 2022, then soared by 104.36% to $135.6 million in 2023, then fell by 5.82% to $127.7 million in 2024, then declined by 8.85% to $125.1 million in 2025.
  • Its Cash & Equivalents stands at $125.1 million for Q3 2025, versus $102.7 million for Q2 2025 and $89.8 million for Q1 2025.